Orion Corporation: Organising meeting of the Board of Directors
The compositions of the Board committees were decided to be as follows:
Heikki Westerlund, Chairman
Mikael Silvennoinen, Chairman
Sirpa Jalkanen, Chairman
The members to the Nomination Committee were elected on 26 October 2017 as stated in the stock exchange release on the same day.
The Board of Directors has assessed the independence of its members and concluded that all the members are independent of the company and its significant shareholders.
|Timo Lappalainen |
President and CEO
|Olli Huotari |
SVP, Corporate Functions
Olli Huotari, SVP, Corporate Functions, Secretary of the Board of Directors, phone +358 50 966 3054
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,085 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki.